Hereditary ovarian cancer: Biology, response to chemotherapy and prognosis

Women's Health

Volumn 5, Issue 5, 2009, Pages 543-553

  Safra, Tamar ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Biomarkers; BRCA1; BRCA2; Chemotherapy sensitivity; Inherited ovarian cancer; PARP inhibitors; Prognosis

Indexed keywords

AZD 2281; BRCA1 PROTEIN; BRCA2 PROTEIN; BSI 201; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOUBLE STRANDED DNA; DOXORUBICIN; GEMCITABINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 2; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PACLITAXEL; UNCLASSIFIED DRUG; ADENOSINE DIPHOSPHATE RIBOSE;

BREAST CANCER; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL CYCLE; CLINICAL TRIAL; DNA DAMAGE; DNA REPAIR; DNA STRAND BREAKAGE; DRUG SENSITIVITY; DRUG TARGETING; FEMALE; GENE MUTATION; HERITABILITY; HUMAN; IN VITRO STUDY; NUMERICAL CHROMOSOME ABERRATION; OVARY CANCER; PREDICTION; PROGNOSIS; REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ANTAGONISTS AND INHIBITORS; GENETIC PREDISPOSITION; GENETICS; MUTATION; OVARIAN NEOPLASMS; PATHOLOGY; RISK FACTOR; TUMOR SUPPRESSOR GENE; UNITED STATES;

ADENOSINE DIPHOSPHATE RIBOSE; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; OVARIAN NEOPLASMS; PROGNOSIS; RISK FACTORS; UNITED STATES;

EID: 69849093693     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.09.40     Document Type: Review

References (100)

1. Hartwell LH, Kastan MB: Cell cycle control and cancer. Science 266(5192), 1821-1828 (1994).
2. Jemal A, Siegel R, Ward E et al.: Cancer statistics, 2006. CA Cancer J. Clin. 56, 106-130 (2006).
3. Ries LAG, Harkins D, Krapcho M et al.: SEER Cancer Statistics Review, 1975-2003, National Cancer Institute Bethesda MD.
4. Claus EB, Schildkraut JM, Thompson WD et al.: The genetic attributable risk of breast and ovarian cancer. Cancer 77, 2318-2324 (1996).
5. Risch HA, McLaughlin JR, Cole DE et al.: Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am. J. Hum. Genet. 68, 700-710 (2001).
6. Hirsh-Yechezkel G, Chetrit A, Lubin F et al.: Population attributes affecting the prevalence of BRCA mutation carriers in epithelial ovarian cancer cases in Israel. Gynecol. Oncol. 89, 494-498 (2003).
7. Modan B, Hartge P, Hirsh-Yechezkel G et al.: Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N. Engl. J. Med. 345, 235-240 (2001).
8. Levy-Lahad E, Friedman E: Cancer risks among BRCA1 and BRCA2 mutation carriers. Br. J. Cancer 96, 11-15 (2007).
9. Rubin SC, Benjamin I, Behbakht K et al.: Clinical and pathologic features of ovarian cancer in women with germ-line mutations of BRCA1. N. Engl. J. Med. 335, 1413-1416 (1996).
10. Boyd J, Sonoda Y, Federici MG et al.: Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 283, 2260-2265 (2000).
11. Ramus SJ, Fishman A, Pharoah PDP et al.: Ovarian cancer survival in Ashkenazi Jewish patients with BRCA1 and BRCA2 mutations. Eur. J. Surg. Oncol. 27, 278-281 (2001).
12. Cass I, Baldwin RL, Varkey T et al.: Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 97, 2187-2195 (2003).
13. Pharoah PDP, Easton DF, Stockton DL et al.: Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. Cancer Res. 59, 868-871 (1999).
14. Aida H, Takakuwa K, Nagata H et al.: Clinical features of ovarian cancer in Japanese women with germ-line mutations of BRCA1. Clin. Cancer Res. 4, 235-240 (1998).
15. Jóhannsson OT, Ranstam J, Borg A et al.: Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. J. Clin. Oncol. 16, 397-404 (1998).
16. Pal T, Permuth-Wey J, Kapoor R et al.: Improved survival in BRCA2 carriers with ovarian cancer. Fam. Cancer 6, 113-119 (2007).
17. Tan DS, Rothermundt C, Thomas K et al.: 'BRCAness' syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J. Clin. Oncol. 26, 5530-5536 (2008).
18. David BY, Chetrit A, Hirsh-Yechezkel G et al.: Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J. Clin. Oncol. 20, 463-466 (2002).
19. Kringen P, Wang Y, Dumeaux V et al.: TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival. BMC Cancer 5, 134 (2005).
20. Buller RE, Shahin MS, Geisler JP et al.: Failure of BRCA1 dysfunction to alter ovarian cancer survival. Clin. Cancer Res. 8, 1196-1202 (2002).
21. Zweemer RP, Verheijen RH, Coebergh JW et al.: Survival analysis in familial ovarian cancer, a case control study. Eur. J. Obstet. Gynecol. Reprod. Biol. 98, 219-223 (2001).
22. Chetrit A, Hirsh-Yechezkel G, Ben-David Y et al.: Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the National Israeli Study of Ovarian Cancer. J. Clin. Oncol. 26, 20-25, (2008).
23. Whittemore AS, Gong G, Itnyre J: Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three US population-based case-control studies of ovarian cancer. Am. J. Hum. Genet. 60, 496-504 (1997).
24. Rubin SC: BRCA-related ovarian carcinoma. Cancer 97, 2127-2129 (2003)
25. Hartge P, Struewing JP, Wacholder S et al.: The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am. J. Hum. Genet. 64, 963-970 (1999).
26. Johannesdottir G, Gudmundsson J, Bergthorsson JT et al.: High prevalence of the 999del5 mutation in Icelandic breast and ovarian cancer patients. Cancer Res. 56, 3663-3665 (1996).
27. Huusko P, Pääkkönen K, Launonen V et al.: Evidence of founder mutations in Finnish BRCA1 and BRCA2 families. Am. J. Hum. Genet. 62, 1544-1548 (1998).
28. Peelen T, Vliet M van, Petrij-Bosch A et al.: A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families. Am. J. Hum. Genet. 60, 1041-1049 (1997).
29. Tonin P, Mes-Masson A, Futreal P et al.: Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. Am. J. Hum. Genet. 63, 1341-1351 (1998).
30. Górski B, Byrski T, Huzarski T et al.: Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. Am. J. Hum. Genet. 66(6), 1963-1968 (2000).
31. Filippini S, Blanco A, Fernández-Marmiesse A et al.: Multiplex SNaPshot for detection of BRCA1/2 common mutations in Spanish and Spanish related breast/ovarian cancer families. BMC Med. Genet. 8, 40-46 (2007).
32. Hartge P, Struewing JP, Wacholder S et al.: The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am. J. Hum. Genet. 64, 963-970 (1999).
33. Bahar AY, Taylor PJ, Andrews L et al.: The frequency of founder mutations in the BRCA1, BRCA2, and APC genes in Australian Ashkenazi Jews: implications for the generality of US population data. Cancer 92, 440-445 (2001).
34. Moslehi R, Chu W, Karlan B et al.: BRCA1 and BRCA2 mutation ana lysis of 208 Ashkenazi Jewish women with ovarian cancer. Am. J. Hum. Genet. 66, 1259-1272 (2000).
35. Frank TS, Deffenbaugh AM, Reid JE et al.: Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: ana lysis of 10,000 individuals. J. Clin. Oncol. 20, 1480-1490 (2002).
36. King TA, Li W, Brogi E, Yee C et al.: Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis. Ann. Surg. Oncol. 14, 2510-2518 (2007).
37. Knudson AG Jr: Mutation and cancer: statistical study of retinoblastoma. Proc. Natl Acad. Sci. USA 68 (4) (1971).
38. Catteau A, Harris WH, Xu CF, Solomon E: Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene 18, 1957-1965 (1999).
39. Russell PA, Pharoah PD, De Foy K et al.: Frequent loss of BRCA1 mRNA and protein expression in sporadic ovarian cancers. Int. J. Cancer 87, 317-321 (2000).
40. Brose MS, Rebbeck TR, Calzone KA et al.: Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. JNCI 94, 1365-1372 (2002).
41. King MC, Marks JH, Mandell JB et al.: Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302, 643-646 (2003).
42. Narod SA, Feunteun J, Lynch HT et al.: Familial breast-ovarian cancer locus on chromosome 17q12-q23. Lancet 338, 82-83 (1991).
43. Miki Y, Swensen J, Shattuck-Eidens D et al.: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266, 66-71 (1994).
44. Struewing JP, Abeliovich D, Peretz T et al.: The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat. Genet. 11, 198-200 (1995).
45. Wooster R, Bignell G, Lancaster J et al.: Identification of the breast cancer susceptibility gene BRCA2. Nature 378, 789-792 (1995).
46. Neuhausen S, Gilewski T, Norton L et al.: Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nat. Genet. 13, 126-128 (1996).
47. Couch FJ, Weber BL: Mutations and poymorphisms in the familial early-onset breast cancer (BRCA1) gene. Breast cancer information core. Hum. Mutat. 8, 8-18 (1996).
48. Roa BB, Boyd AA, Volcik K, Richards CS: Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat. Genet. 14, 185-187 (1996).
49. Welcsh PL, King MC: BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum. Mol. Genet. 10, 705-713 (2001).
50. Kinzler KW, Vogelstein B: Cancer-susceptibility genes. Gatekeepers and caretakers. Nature 386, 761-762 (1997).
51. Rahman N, Stratton MR: The genetics of breast cancer susceptibility. Annu. Rev. Genet. 32, 95-121 (1998).
52. Nathanson KN, Wooster R, Weber BL: Breast cancer genetics: what we know and what we need. Nat. Med. 7, 552-556 (2001).
53. Hashizume R, Fukuda M, Maeda I et al.: The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. J. Biol. Chem. 276, 14537-14540 (2001).
54. Kanaar R, Hoeijmakers JH, van Gent DC: Molecular mechanisms of DNA double strand break repair. Trends Cell Biol. 8, 483-489 (1998).
55. Venkitaraman AR: Linking the cellular functions of BRCA genes to cancer pathogenesis and treatment. Annu. Rev. Pathol. 4, 461-487 (2009).
56. Ruffner H, Joazeiro CA, Hemmati D, Hunter T, Verma IM: Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity. Proc. Natl Acad. Sci. USA 98, 5134-5139 (2001).
57. Brzovic PS, Rajagopal P, Hoyt DW, King MC, Klevit RE: Structure of a BRCA1-BARD1 heterodimeric RING-RING complex. Nat. Struct. Biol. 8, 833-837 (2001).
58. Hashizume R, Fukuda M, Maeda I et al.: The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. J. Biol. Chem. 276, 14537-14540 (2001).
59. Ruffner H, Joazeiro CA, Hemmati D, Hunter T, Verma IM: Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity. Proc. Natl Acad. Sci. USA 98, 5134-5139 (2001).
60. Brzovic PS, Rajagopal P, Hoyt DW, King MC, Klevit RE: Structure of a BRCA1-BARD1 heterodimeric RING-RING complex. Nat. Struct. Biol. 8, 833-837 (2001).
61. Venkitaraman AR: Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108, 171-182 (2002).
62. Venkitaraman AR: Tracing the network connecting BRCA and Fanconi anaemia proteins. Nat. Rev. Cancer 4, 266-276 (2004).
63. Chen J, Silver DP, Walpita D et al.: Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells. Mol. Cell 2, 317-328 (1998).
64. Xu X, Weaver Z, Linke SP, Li C et al.: Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol. Cell 3, 389-395 (1999).
65. Wang B, Matsuoka S, Ballif BA et al.: Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response. Science 316, 1194-1198 (2007).
66. Sobhian B, Shao G, Lilli DR et al.: RAP80 targets BRCA1 to specific ubiquitin structures at DNA damage sites. Science 316, 1198-1202 (2007).
67. Kim H, Chen J, Yu X: Ubiquitin-binding protein RAP80 mediates BRCA1-dependent DNA damage response. Science 316, 1202-1205 (2007).
68. Scully R, Chen J, Plug A et al.: Association of BRCA1 with RAD51 in mitotic and meiotic cells. Cell 88, 265-275 (1997).
69. Harkin DP, Bean JM, Miklos D et al.: Induction of GADD45 and JNK/ SAPK-dependent apoptosis following inducible expression of BRCA1. Cell 97, 575-586 (1999).
70. Phillips KA, Nichol K, Ozcelik H et al.: Frequency of p53. J. Natl Cancer Ins. 91(5), 469-473 (1999).
71. West SC: Molecular views of recombination proteins and their control. Nat. Rev. Mol. Cell. Biol. 4, 435-445 (2003).
72. Patel KJ, Yu VPCC, Lee H et al.: Involvement of BRCA2 in DNA repair. Mol. Cell 1, 347-357 (1998).
73. Wang RH, Yu H, Deng CX: A requirement for breast-cancer-associated gene 1 (BRCA1) in the spindle checkpoint. Proc. Natl Acad. Sci. USA 101, 17108-17113 (2004).
74. Foulkes WD: BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis. Fam. Cancer 5, 135-142 (2006).
75. Quinn JE, Kennedy RD, Mullan PB et al.: BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res. 63, 6221-6228 (2003).
76. Quinn JE, James CR, Stewart GE et al.: BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin. Cancer Res. 13, 7413 (2007).
77. Tassone P, Tagliaferri P, Perricelli A et al.: BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br. J. Cancer 88, 1285-1291 (2003).
78. Lafarge S, Sylvain V, Ferrara M, Bignon YJ: Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene 20, 6597-6606 (2001).
79. Moynahan ME, Chiu JW, Koller BH, Jasin M: BRCA1 controls homology-directed DNA repair. Mol. Cell 4, 511-518 (1999).
80. Fedier A, Steiner RA, Schwarz VA, Lenherr L, Haller U, Fink D: The effect of loss of BRCA1 on the sensitivity to anticancer agents in p53-deficient cells. Int. J. Oncol. 22, 1169-1173 (2003).
81. Sgagias MK, Wagner KU, Hamik B et al.: BRCA1-deficient murine mammary epithelial cells have increased sensitivity to CDDP and MMS. Cell Cycle 3, 1451-1456 (2004).
82. Chappuis PO, Goffin J, Wong N et al.: A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer. J. Med. Genet. 39, 608-610 (2002).
83. Kirova YM, Stoppa-Lyonnet D, Savignoni A, Sigal-Zafrani B, Fabre N, Fourquet A: Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy. Eur. J. Cancer 41, 2304-2311 (2005).
84. Thrall M, Gallion HH, Kryscio R, Kapali M, Armstrong DK, DeLoia JA: BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study. Int. J. Gynecol. Cancer 1, 166-171 (2006).
85. Husain A, He G, Venkatraman ES, Spriggs DR: BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res. 58, 1120-1123 (1998).
86. Sylvain V, Lafarge S, Bignon YJ: Dominant-negative activity of a BRCA1 truncation mutant: effects on proliferation, tumorigenicity in vivo, and chemosensitivity in a mouse ovarian cancer cell line. Int. J. Oncol. 20, 845-853 (2002).
87. Mullan PB, Quinn JE, Gilmore PM et al.: BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents. Oncogene 20, 6123-6131 (2001).
88. Chabalier C, Lamare C, Racca C et al.: BRCA1 down-regulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. Cell Cycle 5, 1001-1007 (2006).
89. Patel K, Yu V, Lee H et al.: Involvement of BRCA2 in DNA repair. Mol. Cell 1(3), 347-357 (1998).
90. Donoho G, Brenneman MA, Cui TX et al.: Deletion of BRCA2 exon 27 causes hypersensitivity to DNA crosslinks, chromosomal instability, and reduced life span in mice. Genes Chromosomes Cancer 36(4), 317-331 (2003).
91. Bartz SR, Zhang Z, Burchard J et al.: Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. Mol. Cell. Biol. 26(24), 9377-9386 (2006).
92. Wang W, Figg WD: Secondary BRCA1 and BRCA2 alterations and acquired chemoresistance. Cancer Biol. Ther. 7(7), 1004-1005 (2008).
93. Boulton S, Kyle S, Durkacz BW: Interactive effects of inhibitors of poly (ADP-ribose) polymerase and DNA-dependent protein kinase on cellular responses to DNA damage. Carcinogenesis 20, 199-203 (1999).
94. Saffhill R, Ockey CH: Strand breaks arising from the repair of the 5-bromodeoxyuridine-substituted template and methyl methanesulphonate-induced lesions can explain the formation of sister chromatid exchanges. Chromosoma 92, 218-224 (1985).
95. Schultz N, Lopez E, Saleh-Gohari N, Helleday T: Poly (ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination. Nucleic Acids Res. 31, 4959-4964 (2003).
96. Audeh MW, Penson RT, Friedlander M et al.: Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer. J. Clin. Oncol. 27, 15S; Abstract 5500 (2009).
97. Fong PC, J. Spicer, Reade S et al.: Phase I pharmacokinetic (PK) and pharmacodynamic (PD) evaluation of a small molecule inhibitor of Poly ADP-Ribose Polymerase (PARP), KU-0059436 (Ku) in patients (p) with advanced tumours. J. Clin. Oncol. 24, 18S; Abstract 3022 (2006).
98. O'Shaughnessy J, Osborne C, Pippen J et al.: Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized Phase II trial. J. Clin. Oncol. 27, 18S; Abstract 3 (2009).
99. Hennessy B, Timms K, Carey MS et al.: Somatic BRCA status in ovarian tumors. J. Clin. Oncol. 27, 15S; Abstract 5528 (2009).
100. Tutt A, Robson M, Garber JE et al.: Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J. Clin. Oncol. 27, 18S; Abstract CRA501 (2009).